Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
Science Daily2 天
Parkinson's Research News
which could lead to treatments for the cognitive symptoms of Parkinson's disease ... New Drug Targets for Alzheimer's Identified from Cerebrospinal Fluid Nov. 14, 2024 — Researchers have linked ...
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.
PharmTech4 天
European Biotechs Unlocking Parkinson’s Disease
Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
globes.co.il3 天
"The best Parkinson's medication will be Israeli, and hybrid"
"The best medication for Parkinson's will come from Israel. It will be a hybrid medication, and the world's best hybrid ...
AbbVie's Parkinson's disease drug meets main goal in late-stage study
(Reuters) -AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.